The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

NCT06833307 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis

Interventions

DRUG: SHR-1314

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.